# EDGAR Filing Document

**Accession Number:** 0001038277
**File Stem:** 0001437749-25-039001
**Filing Date:** 2025-12
**Character Count:** 10708
**Document Hash:** 50aeea768b0cd3780935f9cf8a6417a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-039001.hdr.sgml**: 20251231

**ACCESSION NUMBER**: 0001437749-25-039001

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20251223

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251231

**DATE AS OF CHANGE**: 20251231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTERNATIONAL ISOTOPES INC
- **CENTRAL INDEX KEY:** 0001038277
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 742763837
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22923
- **FILM NUMBER:** 251615858

**BUSINESS ADDRESS:**
- **STREET 1:** 4137 COMMERCE CIRCLE
- **CITY:** IDAHO FALLS
- **STATE:** ID
- **ZIP:** 83401
- **BUSINESS PHONE:** 2085245300

**MAIL ADDRESS:**
- **STREET 1:** 4137 COMMERCE CIRCLE
- **CITY:** IDAHO FALLS
- **STATE:** ID
- **ZIP:** 83401

?xml version='1.0' encoding='ASCII'? inis20251230_8k.htm

--12-31

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):** 

**December 23, 2025**

**INTERNATIONAL ISOTOPES INC.**

------

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Texas | 0-22923 | 74-2763837 |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

4137 Commerce Circle

<u>Idaho Falls, ID 83401</u>

(Address of Principal Executive Offices) (Zip Code)

<u>208-524-5300</u>

Registrant's telephone number, including area code: (505) 438-2576

<u>N/A</u>

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On December 23, 2025, International Isotopes Inc. ("we," "our," "us," or the "Company") filed a Certificate of Amendment in the state of Texas for the sole purpose of amending our Certificate of Formation to change our corporate name from International Isotopes Inc. to Radnostix, Inc. (the "<u>Name Change</u>"). As was previously disclosed on a Schedule 14C Information Statement filed by the Company with the Securities and Exchange Commission on November 26, 2025, our board of directors approved the Name Change on October 21, 2025, and a majority of shareholders approved the Name Change by written consent on November 25, 2025.

The Name Change was implemented because our line of business has expanded from providing radiochemicals and non-medical radioisotopes and a focus on energy-sector related isotopes to providing a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories, mainly focused on healthcare applications. We believe that Radnostix, Inc. better reflects our focus on radiosiotopes and theranostics going forward.

At this time, our common stock will continue to trade under the current ticket symbol "INIS" on the OTCQB marketplace. Shareholders are not required to take any action regarding their stock certificates as a result of the name change.

**Item 8.01 Other Events.**

On December 31, 2025, the Company issued a press release announcing the Name Change. A copy of the press release is attached here as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [Press Release regarding Name Change dated December 31, 2025.](ex_903318.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: December 31, 2025 | **INTERNATIONAL ISOTOPES INC.** | **INTERNATIONAL ISOTOPES INC.** |
|  | By: | */s/ Shahe Bagerdjian*  |
|  | Name:  | Shahe Bagerdjian |
|  | Title: | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![a01.jpg](a01.jpg) | 1.208.524.5300<br> 4137 Commerce Circle<br> Idaho Falls, ID, USA 83401<br> Radnostix.com |

---

**FOR IMMEDIATE RELEASE**

**International Isotopes Inc. Announces Company Name Change to Radnostix, Inc.**

**Idaho Falls, ID** – **December 31<sup>st</sup>, 2025** – International Isotopes Inc. ("INIS" or the "Company") (OTCQB:INIS) today announced that it has filed a Certificate of Amendment in the State of Texas to change our legal name to Radnostix, Inc. Effective immediately, we will officially begin to rebrand all of our operations under the Radnostix name. INIS was started in 1995 as a company focused on irradiation and manufacturing of industrial radioisotope products. Over the years, our focus has evolved, and the name change reflects the Company's expanding product segments and evolving strategic focus on radioisotopes and theranostics products.

While the International Isotopes Inc. branding will no longer be our flagship, the INIS branding will be re-utilized around our segments which are focused on high energy sources, bulk radioisotopes, and stable isotopes. Our other brands, Radqual, Radvent, Easyfill, Benchmark, and PhanQual, will continue going forward under the umbrella of Radnostix, Inc. The Company's operations, management team, and commitment to its customers and partners remain unchanged.

"The name Radnostix better encapsulates our mission to become the premiere industry partner in the radioisotope & theranostics space. While our name is changing, our dedication to quality, innovation, and customer service and our strategic direction remain steadfast" said Radnostix CEO, Shahe Bagerdjian.

At this time, the Company's common stock will continue to trade under its current ticker symbol "INIS" on the OTCQB marketplace. Further information regarding a potential new ticker symbol, if any, will be announced in due course. Shareholders are not required to take any action regarding their stock certificates as a result of the name change.

***About Radnostix (formerly International Isotopes Inc.):***<br> Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products. For more information, visit radnostix.com.

![a02.jpg](a02.jpg)

------

![a03.jpg](a03.jpg)

***Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:***<br> Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. and the Company undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Radnostix Contact:** <br> <u>ir@intisoid.com<br> radnostix.com<br> intisoid.com</u><br> 208.524.5300

**Investor Relations Contact:**<br> David Drewitz, Creative<br> Options Communications Investor and Public Relations<br> <u>david@creativeoptionscommunications.com<br> creativeoptionsmarketing.com</u><br> 972.814.5723

**-END-**

![a02.jpg](a02.jpg)